Sandeep Khurana, MD
Cardiovascular Disease · Grandville, MINPI 1720063787
Payments from drug & device makers
Across 643 payments — averaging $3516.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.7M
- Novartis$158K
- Boehringer Ingelheim$116K
- Regeneron$104K
- Esperion Therapeutics, Inc.$97K
- Sanofi-aventis U.S. LLC$38K
- plus $93K from 23 others
Across 3 payments — averaging $545.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 91 | $1,656,076 |
| Novartis | 26 | $157,970 |
| Boehringer Ingelheim | 31 | $115,955 |
| Regeneron | 26 | $103,511 |
| Esperion Therapeutics, Inc. | 155 | $96,813 |
| Sanofi-aventis U.S. LLC | 29 | $37,546 |
| Boehringer Ingelheim International GmbH | 97 | $30,148 |
| CSL Behring | 39 | $22,709 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $19,518 |
| Bayer | 22 | $10,865 |
| Regeneron Healthcare Solutions, Inc. | 11 | $4,585 |
| Novo Nordisk | 22 | $1,515 |
| Merck | 8 | $1,406 |
| Pfizer | 21 | $854 |
| Amarin Pharma, Inc. | 39 | $403 |
| Alnylam Pharmaceuticals Inc. | 3 | $320 |
| AstraZeneca | 4 | $283 |
| Cequr Corporation | 1 | $201 |
| Xeris Pharmaceuticals, Inc. | 3 | $182 |
| Lilly USA, LLC | 1 | $109 |
| Bridgebio Pharma, Inc. | 1 | $109 |
| Dexcom, Inc. | 2 | $81 |
| Kestra Medical Technology Services, Inc. | 1 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Preventice Services, LLC | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Amryt Pharma Holdings Ltd | 1 | $11 |
How this compares
$2,261,324 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Grandville
- Stanley ChetcutiAnn Arbor$4.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
- Ahmad MizyedYpsilanti$1M
- Waleed DoghmiMidland$968K
- David HainesRoyal Oak$954K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.